Previous close | 3.7500 |
Open | 3.7500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 170.00 |
Expiry date | 2025-01-17 |
Day's range | 3.7500 - 3.7500 |
Contract range | N/A |
Volume | |
Open interest | 236 |
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Bioscience
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.